Results for tag: "Open Angle Glaucoma Drugs"

Open-angle glaucoma is a common type of glaucoma often characterized by an increase in intraocular pressure, which can lead to optic nerve damage and, if untreated, loss of vision. Open-angle glaucoma drugs are a subset of optical disorders drugs, aimed specifically at managing this condition. These medications typically strive to decrease intraocular pressure through various mechanisms, such as reducing the production of aqueous humor (the clear fluid in the eye) or increasing its outflow from the eye. The market comprises several classes of drugs, including prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, and rho kinase inhibitors. Often these drugs are used in combination to achieve better control over eye pressure. Treatment for open-angle glaucoma is a crucial component of the broader optical disorders drugs market, which addresses a spectrum of conditions affecting vision, such as age-related macular degeneration, diabetic retinopathy, and cataracts. While therapies for these conditions can vary widely, the approach to managing open-angle glaucoma is more focused on pressure regulation within the eye to prevent or reduce damage to the optic nerve and maintain the patient's functional vision. Several key players in the open-angle glaucoma drugs market include Pfizer, Allergan (now part of AbbVie), Merck & Co., Novartis, and Santen Pharmaceutical. These companies have stayed at the forefront by offering a diverse portfolio of treatments and by investing in the development Show Less Read more